Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Favorable Long-Term PIII Results Published for Collategene: AnGes MG
December 20, 2010
- Revolade Benefits Patients with Intractable ITP: Prof. Ikeda
December 20, 2010
- Daiichi Sankyo Subsidiary Luitpold Acquires ROXRO PHARMA
December 20, 2010
- Daiichi Sankyo Completes Enrollment for Edoxaban PIII Trial
December 20, 2010
- Norspan Useful in Getting Doctors Conversant with Opioids: Prof. Ogawa
December 20, 2010
- Sanofi-aventis Extends Tender Offer for Genzyme Shares
December 20, 2010
- Novel Anticoagulants Gaining Popularity: Dr Yamashita
December 20, 2010
- Fixed-Dose Combination Eye Drops Improve Compliance: Dr Araie
December 20, 2010
- Mediscience to Acquire CRO Business from Tokyo Clinical CRO
December 20, 2010
- Industry Support Essential for iPS Cell Drug Discovery: Prof. Yamanaka
December 20, 2010
- NCGM Compiles Manual for Selection of Antidiabetic Drugs for GPs
December 20, 2010
- MTPC Takes Confidence-Building Measures
December 20, 2010
- JPMA Willing to Support iPS Drug Discovery: President Hasegawa
December 20, 2010
- Eisai, SymBio: Anticancer Agent TREAKISYM
December 20, 2010
- Sanofi Pasteur to Enhance Its Presence in Japan: General Manager Perraudin
December 20, 2010
- NPhA Casts Doubt on Drug Wholesalers' Rx Pharmacy Business
December 20, 2010
- Takeda, Daiichi Sankyo, Astellas Lead Drug Firms' Corporate Image Ranking
December 20, 2010
- Kyorin Turns Down Sawai's Merger Proposal Again
December 20, 2010
- NBI Takes Over Mobic Marketing from Daiichi Sankyo
December 13, 2010
- Lubiprostone Shows Favorable Safety, Tolerability in PIII: Sucampo, Abbott
December 13, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…